The Food and Drug Administration is looking to speed up the approval times for generic medications, an effort FDA Commissioner Scott Gottlieb says is a key contribution to help the Trump administration deliver on its pledge for lower drug costs.
According to a Reuter’s report, Gottlieb says the Department of Health and Human Services is leading the initiative.
“So we’re doing it on the generic side, but we’re also thinking of doing it on the new drug side,” Gottlieb said during an interview at the American Society of Clinical Oncology’s Chicago meeting.
Gottlieb said companies with a high investment in their products should have more control over their pricing.
“They’re going to have a monopoly, but that monopoly shouldn’t last forever,” Gottlieb said. “That’s what we’re trying to facilitate.”